- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00096226
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving paclitaxel and carboplatin together with radiation therapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any tumor cells remaining after surgery.
PURPOSE: This phase II trial is studying how well giving paclitaxel and carboplatin together with radiation therapy works in treating patients who are undergoing surgery for stage III non-small cell lung cancer.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
- Determine the mediastinal node clearance rate in patients with stage IIIA or IIIB non-small cell lung cancer treated with neoadjuvant induction chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose radiotherapy followed by surgical resection for patients found to be resectable and consolidative chemotherapy comprising paclitaxel and carboplatin.
- Determine the rate of complete pathological response in patients treated with this regimen.
- Determine the feasibility of surgical resection after neoadjuvant induction chemoradiotherapy in these patients.
- Determine disease-free and overall survival of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85013
- Arizona Oncology Services Foundation
-
Scottsdale, Arizona, Stati Uniti, 85260
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
-
-
California
-
Los Angeles, California, Stati Uniti, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Mayo Clinic - Jacksonville
-
Tallahassee, Florida, Stati Uniti, 32308
- Tallahassee Memorial Hospital
-
-
Illinois
-
Springfield, Illinois, Stati Uniti, 62702
- Cancer Institute at St. John's Hospital
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Stati Uniti, 48106
- CCOP - Michigan Cancer Research Consortium
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Methodist Estabrook Cancer Center
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cancer Institute of New Jersey at Cooper University Hospital - Camden
-
Voorhees, New Jersey, Stati Uniti, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
-
North Carolina
-
Greenville, North Carolina, Stati Uniti, 27835-6028
- Leo W. Jenkins Cancer Center at ECU Medical School
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- St. Luke's Cancer Network at St. Luke's Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Tennessee
-
Kingsport, Tennessee, Stati Uniti, 37662
- Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
-
-
West Virginia
-
Wheeling, West Virginia, Stati Uniti, 26003
- Schiffler Cancer Center at Wheeling Hospital
-
-
Wisconsin
-
Green Bay, Wisconsin, Stati Uniti, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Medical College of Wisconsin Cancer Center
-
Milwaukee, Wisconsin, Stati Uniti, 53295
- Veterans Affairs Medical Center - Milwaukee
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with Stage IIIA (T1-3 N2) or Stage IIIB (N3, excluding supraclavicular involvement) non-small cell lung cancer documented by biopsy or cytology (Pancoast tumors are eligible if pathologic evidence of mediastinal nodal disease is present);
- Disease must be measurable;
- Mediastinal lymph nodes must be proven positive by pathologic review. All patients must undergo mediastinoscopy, thoracoscopy, Chamberlain procedure, or transbronchial needle aspirate to evaluate extent of nodal involvement. Any lymph node assessed by mediastinoscopy and found to be positive will be defined as N2 disease;
- Patients ≥ 18 years of age;
- Life expectancy ≥ 6 months;
- Zubrod performance status 0- 1 (See Appendix II);
- Pretreatment laboratory values must be as follows: White blood cell count (WBC) count: ≥ 3,000/mm^3; Absolute granulocyte count: ≥ 1,500/mm^3; Platelets: ≥ 100,000/mm3; Total bilirubin: ≤ 1.5 x institutional upper limit of normal (ULN); Serum creatinine: ≤ 1.5 x institutional ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x institutional ULN; serum albumin: ≥ 3.0 g/dL
- Baseline forced expiratory volume (FEV1) must be at least 2.0 liters; if less than 2.0 then V/Q scan is required and projected post-operative FEV1 must be > 800 cc based on the following formula using the quantitative Ventilation/perfusion (V/Q) scan: FEV1 = FEV1 x % perfusion to uninvolved lung from quantitative lung V/Q scan report.
- Patient evaluation and acceptance by thoracic surgery, medical oncology, and radiation oncology; patient must be a potential surgical candidate prior to the initiation of therapy;
- Women of childbearing potential and male participants must practice an effective method of contraception during the study;
Pretreatment evaluations required for eligibility include:
- A complete medical history & physical examination to include Zubrod performance status, neurologic assessment, recent weight loss, usual weight, concurrent non-malignant disease and therapy;
- Location, type, and size of measurable lesion must be recorded prior to treatment;
- Complete blood count (CBC) with differential, platelet count, electrolytes, and Mg++ within 14 days prior to study entry;
- Twelve-channel serum multiple analysis (SMA-12): Total protein, Albumin, Calcium, Glucose, Blood urea nitrogen (BUN), Creatinine, Alkaline Phosphatase, Lactate dehydrogenase (LDH), Total Bilirubin, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) within 14 days prior to study entry;
- Women of childbearing potential must have a negative pre-study serum or urine pregnancy test within 14 days prior to study entry.
- Mediastinoscopy, thoracoscopy, Chamberlain procedure, or bronchoscopy with transbronchial needle aspirate to evaluate the extent of lymph node involvement;
- Computed tomography (CT) scan of the chest to include liver, and adrenal glands within 6 weeks prior to study entry;
- Positron emission tomography (PET) scan within 8 weeks prior to study entry. Any suspicious areas outside of the local regional disease requires documented evaluation of these findings to exclude metastatic disease;
- CT scan or magnetic resonance imaging (MRI) of the brain within 6 weeks prior to study entry;
- Electrocardiogram (EKG) and pulmonary function tests including forced vital capacity (FVC), FEV-1, and diffusing capacity of carbon monoxide (DLCO), within 8 weeks prior to study entry; V/Q scan, if applicable, within 8 weeks prior to study entry.
- Patients must sign a study-specific informed consent prior to study entry.
Exclusion Criteria:
- Small cell lung cancer; distant metastatic disease;
- Evidence of clinical or radiographic supraclavicular lymph node involvement;
- Bronchioalveolar carcinoma with lobar or multilobar involvement;
- Unintentional weight loss > 5% within 6 months prior to study entry, or Zubrod performance status 2 or greater;
- Primary tumor location prevents delivery of 60 Gy and simultaneously limiting spinal cord dose to 48 Gy;
- Patients with malignant pleural effusion;
- Clinically evident superior vena cava syndrome;
- Prior systemic chemotherapy or radiation therapy to the thorax;
- Patients with known hypersensitivity to Cremophor EL;
- Patients receiving other investigational therapy;
- Pregnant or lactating women are ineligible, as treatment involves unforeseeable risks to the participant and to the embryo or fetus;
- Patients with an active serious infection or other serious underlying medical condition that would impair their ability to complete protocol treatment;
- Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Chemoradiation, Surgery, Chemotherapy
Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks.
Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions.
Followed by an assessment to determine whether patient will undergo a resection or not.
Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Mediastinal Nodal Clearance Rate
Lasso di tempo: At completion of concurrent chemotherapy and radiation therapy, up to 14 weeks.
|
If at least 12 of the first 21 evaluable patients and at least 27 of the the first 45 evaluable patients have mediastinal nodal clearance (MNC), then a conclusion of a 70% MNC rate (compared to 50%) is made using Simon's two-stage design with 90% power and 10% type I error.
|
At completion of concurrent chemotherapy and radiation therapy, up to 14 weeks.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Patients With Complete Pathological Response After Concurrent Chemotherapy and Radiation Therapy
Lasso di tempo: At time of surgery (16-18 weeks)
|
Complete pathologic response is defined as complete resection achieved and no evidence of viable tumor in the entire resection specimen.
|
At time of surgery (16-18 weeks)
|
Percentage of Patients With Major Surgical Morbidities Within 30 Days of Surgery
Lasso di tempo: From 0 to 30 days following surgery (surgery occurs within 16-18 weeks after registration)
|
The surgical morbidities occurring within 30 days following resection were assessed and graded using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.
A major morbidity is considered a grade 3 or higher of any of the following: pneumonitis, infection, atelectasis, chest tube drainage/bronchial stump leak, pneumothorax, chylothorax, cardiac ischemia/infarction, pulmonary thrombosis/embolism, supraventricular atrial arrhythmia, ventricular arrhythmia, post-operative hemorrhage, pulmonary/upper respiratory fistula, pleural effusion, or death.
|
From 0 to 30 days following surgery (surgery occurs within 16-18 weeks after registration)
|
Percentage of Patients Able to Undergo Surgical Resection
Lasso di tempo: At time of surgery (16-18 weeks)
|
At time of surgery (16-18 weeks)
|
|
Distribution of R0, R1, and R2 Resections After Chemotherapy
Lasso di tempo: At time of surgery (16-18 weeks)
|
An R0 resection is defined as a complete resection of all disease with negative margins and the highest lymph node resected negative for residual tumor.
An R1 resection is defined as a complete resection of all disease with pathology of positive margins, pathologic evidence of tumor cells in the highest lymph node resected in the mediastinum, or extracapsular nodal spread.
An R2 resection is defined as gross residual disease left behind after surgical resection.
|
At time of surgery (16-18 weeks)
|
Overall Survival at Two Years
Lasso di tempo: From registration to two years
|
Overall survival time is defined as time from registration to the date of death from any cause.
Overall survival rate is estimated by the Kaplan-Meier method.
Patients last known to be alive are censored at the date of last contact.
|
From registration to two years
|
Progression-free Survival at Two Years
Lasso di tempo: From registration to two years
|
Progression is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or the appearance of one or more new lesions.
An event for progression-free survival is the first occurrence of progression or death due to any cause.
Progression-free survival time is defined as the time from study entry to the the date progression or death, or last known follow-up (censored) if neither progression nor death occurred.
Progression-free survival rate is estimated using the Kaplan-Meier method.
|
From registration to two years
|
Distribution of Highest Grade Adverse Event
Lasso di tempo: From start of treatment to end of follow-up, a maximum of 64.3 months
|
The number of patients whose highest grade adverse event (AE) reported was 3, 4, or 5 was calculated.
Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Grade refers to the severity of the AE.
The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Number of patients with highest grade of 3, 4, and 5 are presented.
|
From start of treatment to end of follow-up, a maximum of 64.3 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Mohan Suntharalingam, MD, University of Maryland Greenebaum Cancer Center
Pubblicazioni e link utili
Pubblicazioni generali
- Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):456-63. doi: 10.1016/j.ijrobp.2011.11.069. Epub 2012 Apr 28.
- Suntharalingam M, Paulus R, Edelman MJ, et al.: RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC. [Abstract] J Clin Oncol 28 (Suppl 15): A-7024, 2010.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Agenti antineoplastici, fitogenici
- Carboplatino
- Paclitaxel
- Paclitaxel legato all'albumina
Altri numeri di identificazione dello studio
- RTOG-0229
- CDR0000389508
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro ai polmoni
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Novartis PharmaceuticalsAttivo, non reclutanteEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaTaiwan, Stati Uniti, Olanda, Spagna, Corea, Repubblica di, Italia, Giappone, Canada, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
University of ChicagoNational Cancer Institute (NCI)CompletatoAdenocarcinoma pancreatico | Adenocarcinoma gastrico | Adenocarcinoma pancreatico metastatico | Neoplasia gastrointestinale maligna | Cancro al pancreas in stadio III | Cancro al pancreas in stadio IV | Carcinoma della cistifellea | Cancro alla cistifellea in stadio IV | Cancro gastrico in stadio IV | Cancro... e altre condizioniStati Uniti
Prove cliniche su Radioterapia
-
Alpha Tau Medical LTD.ReclutamentoCancro della pelle | Neoplasia mucosa della cavità orale | Neoplasia dei tessuti molliItalia
-
Alpha Tau Medical LTD.TerminatoCancro al seno metastatico | Carcinoma al seno | Cancro al seno invasivo | Metastasi a distanza. PatologiaFederazione Russa
-
Abramson Cancer Center at Penn MedicineReclutamentoCancro cervicale | Cancro uterinoStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Reclutamento
-
University of AmsterdamAcademic Center for Trauma and Personality; Arkin Mental Health CareIscrizione su invitoDisturbo borderline di personalitàOlanda
-
EP SciencesSconosciutoElettrofisiologia cardiacaStati Uniti
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)Attivo, non reclutanteIctus | Afasia | Afasia non fluenteStati Uniti
-
Karadeniz Technical UniversityCompletatoEmodialisi | Solitudine | Felicità | Adattamento | Terapia assistita da animali | SintomoTacchino
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale Hochschule...Completato
-
Zealand University HospitalUniversity of Copenhagen; Technical University of Denmark; OptoCeuticsCompletatoMalattia di AlzheimerDanimarca